Our Clinical Trials

Clinical trials are an important aspect of our research and we have a very active roster. The Naomi Berrie Diabetes Center is the site for one of the country’s largest programs of clinical trials in Type 1 diabetes, particularly those involving children.

"Clinical trials benefit everyone."

Robin S. Goland, MD
Co-Founder and Co-Director

A clinical trial sets out to provide research scientists and doctors with answers to specific questions in a clinical setting. People who volunteer for clinical trials, or studies, play an indispensable role in helping find better ways to prevent, diagnose or treat diabetes.

Click here to support clinical trials at the Berrie Center. 

An inside track to our clinical trials

Clinical trials are going on at the Berrie Center all the time. Here are some that are currently enrolling patients. Many patients enroll in trials when their doctors think they may benefit. Feel free to discuss a trial with your doctor if you (or your child) fit the description.

Click on the clinical trial for more information:

Noninvasive Imaging of Pancreatic Beta Cell Mass Using PET Scan

Purpose of Study

The goal of this study is to learn if we can image the pancreatic beta cell, the insulin-producing cell, by PET scanning.

Type of diabetes:

Subjects with type 1 diabetes, type 2 diabetes, healthy non-diabetic subjects

Age:

18-60 years

Time Commitment:

2 half days.  The first visit is for a glucose tolerance test.  The second visit is for a PET scan and CT scan of the abdomen.

Reimbursement:

$350 at completion of the PET and CT scans.

Contact:

Patricia Kringas, RN at (212) 851-5489 or email mpk40@columbia.edu

Oral Insulin Study

Purpose of Study

To determine whether a daily oral insulin capsule can prevent or delay type 1 diabetes in at-risk relatives of people with type 1 diabetes.

Time Commitment:

A blood test every 6 months.

Reimbursement:

Patients receive study drugs and glucose testing supplies at no cost during the study.  Patients are also reimbursed for each visit.

Contact:

Ellen Greenberg, M.S. at (212) 851-5425 or email emg25@columbia.edu

Skin Biopsies for the Generation of Disease-Specific Stem Cells

Purpose of Study

The aim of this study is to develop stem cell lines that have the characteristics of people with diabetes.

Type of diabetes:

Patients with type 1 diabetes or MODY

Age:

>1 year of age

Time Commitment:

Subjects will have a skin biopsy (1/8 inch in diameter) and a blood draw at a Berrie Center visit.

Reimbursement:

none

Contact:

Ellen Greenberg, M.S. at (212) 851-5425 or email emg25@columbia.edu

Study of Immune Function in Type 1 Diabetes: Subjects Wanted to Undergo Bone Marrow Aspiration

Purpose of Study

The aim of this study is to identify immune alterations that characterize type 1 diabetes.

Type of diabetes:

Subjects with type 1 diabetes and non-diabetic healthy subjects with no family history of diabetes are eligible.

Age:

18 and older

Time Commitment:

2 Berrie Center visits; 1 visit for blood draw and return visit for bone marrow aspirate.

Reimbursement:

$25 for visit 1 and $250 for visit including bone marrow aspirate.

Contact:

Ellen Greenberg, M.S. at (212) 851-5425 or email emg25@columbia.edu

Teplizumab (Anti-CD3) for Prevention of Type 1 Diabetes

Purpose of Study

To determine whether an investigational agent teplizumab (antiCD3) preserves insulin secretion and pancreatic beta cell function in subjects who have impaired glucose tolerance and are at high risk to develop type 1 diabetes. In this study, teplizumab is compared to a placebo.

Age:

16-45

Contact:

Ellen Greenberg, M.S. at (212) 851-5425 or email emg25@columbia.edu

TrialNet Type 1 Diabetes Pathway To Prevention Study

Purpose of Study

To screen relatives of type 1 diabetes for the antibodies associated with a higher risk of developing type 1 diabetes. Autoantibodies are a sign that the immune system may be attacking the insulin-producing cells in the pancreas. Click to view the related consent form and assent form

Time Commitment:

One-time blood test.

Contact:

Ellen Greenberg, M.S. at (212) 851-5425 or email emg25@columbia.edu

Type 2 Diabetes Onset in Adolescence and Youth: Genetics Study

Purpose of Study

The aim of this study is to identify the genes responsible for adolescent-onset type 2 diabetes.

Age:

Any age; diabetes onset prior to age 18

Contact:

Patricia Kringas, RN at (212) 851-5489 or email mpk40@columbia.edu

GRADE Study (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness)

Purpose of Study

To compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating T2D.

Type of diabetes:

Patients with type 2 diabetes

Age:

30 years and older

Reimbursement:

You will receive two medicines and four annual medical visits free of charge for the length of the study—and all the diabetes support and education you need to structure a healthy lifestyle and experience good diabetes control and management.

Contact:

Patricia Kringas, research coordinator at (212) 212-851-5489or email mpk40@columbia.edu

CTLA-4 Ig (Abatacept) For Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus

Purpose of Study

To determine whether an investigational agent abatacept (CTLA4-Ig) preserves insulin secretion and pancreatic beta cell function in subjects who have impaired glucose tolerance and are at high risk to develop type 1 diabetes. In this study, abatacept is compared to a placebo.

Funded by the National Institutes of Health 

Type of diabetes:

Type 1 diabetes

Time Commitment:

15 visits during the first year and then twice a year for at least 5 years.

Reimbursement:

$25 per visit for short visits and $50 per visit for long visits.

Contact:

Ellen Greenberg, M.S. at (212) 851-5425or email emg25@columbia.edu

Type 1 Diabetes TrialNet Long-Term Investigative Follow-Up (LIFT) Study

Purpose of Study

To assess long-term effects of experimental treatment of diabetes and to learn whether participating in a TrialNet study has affected your diabetes over time.

Funded by the National Institutes of Health 

Type of diabetes:

Type 1 diabetes

Time Commitment:

Once or twice a year (depending on your c-peptide laboratory test results) for at least 5 years

Reimbursement:

$25 per visit

Contact:

Ellen Greenberg, M.S. at (212) 851-5425or email emg25@columbia.edu